Jazz Pharmaceuticals Showcases Oncology Progress at Key Investor Events in January 2026

Jazz Pharmaceuticals Prepares for Key Investor Events Highlighting Oncology Progress

Jazz Pharmaceuticals plc is poised to showcase its commitment to advancing cancer treatment during two significant investor events in January 2026. The company is set to hold an investor webcast on January 9, where it will present results from the Phase 3 zanidatamab HERIZON-GEA-01 trial. This webcast features insights from senior management and Dr. Geoffrey Ku of Memorial Sloan Kettering Cancer Center, reflecting Jazz's dedication to transparency and engagement with stakeholders. The findings from this trial could provide critical insights into the efficacy and potential market impact of zanidatamab, an innovative therapeutic option targeting HER2-positive malignancies.

The timing of this webcast aligns with an oral presentation at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) on January 8, emphasizing the importance of this research within the broader oncology landscape. By participating in such high-profile events, Jazz Pharmaceuticals not only highlights its ongoing efforts in cancer research but also strengthens its position as a leader in the biopharmaceutical industry. The insights shared during these engagements are expected to inform investors and healthcare professionals about the company's strategies and innovations essential for improving patient outcomes.

Following the webcast, CEO Renee Gala will further detail the company's strategic vision during the 44th Annual J.P. Morgan Healthcare Conference on January 13. This presentation offers Jazz an opportunity to articulate its overall business strategy and recent developments directly to a global audience of investors and industry stakeholders. As the company expands its portfolio beyond sleep disorders and epilepsy into cancer therapies, these events will be crucial in reinforcing its commitment to developing life-changing medicines for patients facing serious diseases.

In addition to its focus on oncology, Jazz Pharmaceuticals operates a diverse portfolio that underscores its commitment to neuroscience and other therapeutic areas. The company, headquartered in Dublin, Ireland, has established a global presence with research and development laboratories as well as manufacturing facilities in multiple countries. As it prepares for these pivotal events, Jazz remains dedicated to innovation and enhancing the quality of life for patients worldwide.

For more information about Jazz Pharmaceuticals and its upcoming presentations, stakeholders can visit the Investors section of the company's website, where replays of the webcasts will be available for 30 days following the live events.